A securities class action has been initiated against Corcept Therapeutics, with allegations that the company misrepresented the regulatory prospects of its flagship drug candidate relacorilant to investors. According to the complaint, Corcept proceeded with public statements expressing confidence in the medication's approval pathway despite receiving repeated warnings from the FDA regarding insufficient clinical data supporting the application.
The legal action was triggered by a significant equity decline on December 31, 2025, when the FDA issued a Complete Response Letter rejecting Corcept's relacorilant application. The stock fell sharply from $70.20 to $34.80 per share, representing a 50% decline that eliminated approximately $3.6 billion in market capitalization. The sudden rejection underscored a disconnect between the company's public messaging and the regulatory agency's assessment of the submitted clinical evidence.
Investors who believe they sustained losses from the company's statements during the relevant period may file as lead plaintiffs in the case, with a deadline of April 21, 2026. The litigation will likely focus on whether Corcept's executives had access to information regarding FDA concerns that was not disclosed to shareholders, and whether public statements about approval prospects were made with knowledge of material risks.